menu
    • menu
    [{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"NewCo","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"NGM313","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"NGM Biopharmaceuticals","amount2":0.60999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0.60999999999999999,"dosageForm":"","sponsorNew":"NGM Biopharmaceuticals \/ NewCo","highestDevelopmentStatusID":"8","companyTruncated":"NGM Biopharmaceuticals \/ NewCo"}]

    Find Clinical Drug Pipeline Developments & Deals for Mk-3655

    Menu

    Mk-3655

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NGM Biopharmaceuticals

                            U.S.A arrow
                            Pittcon 2025
                            Not Confirmed

                            NGM Biopharmaceuticals

                            U.S.A arrow
                            Pittcon 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mk-3655

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : NewCo

                            Deal Size : $608.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            NGM, KdT License Agreement for NGM313, A Phase 2 FGFR1c/β-Klotho Agonist Candidate

                            Details : Under the licensing agreement, NGM Bio will grant NewCo an exclusive global license for the research, development, and commercialization of NGM313 for the treatment of MASH.

                            Product Name : NGM313

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 19, 2024

                            Lead Product(s) : Mk-3655

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : NewCo

                            Deal Size : $608.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth